Arvinas Q2 2026: first PROTAC approval (VEPPANU) and out-license to Rigel; cash $567.9M

ARVINAS, INC.

First-ever FDA approval of a PROTAC degrader (VEPPANU) for ER+/HER2- ESR1-mutated breast cancer; out-licensed to Rigel Pharmaceuticals.
Cash, cash equivalents, and marketable securities $567.9M as of June 30, 2026, down from $685.4M at Dec 31, 2025.
GAAP R&D expenses $52.6M in Q2 2026 vs $68.6M in Q2 2025; decrease driven by lower compensation and vepdegestrant program costs.
Pipeline milestones: data from ARV-393, ARV-102, ARV-027 expected over next 12 months; ARV-6723 Phase 1 initiation in 3Q 2026.
Cash runway into second half of 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.